Truncation of NS1 Protein Enhances T Cell-Mediated Cross-Protection of a Live Attenuated Influenza Vaccine Virus Expressing Wild-Type Nucleoprotein
暂无分享,去创建一个
Irina Isakova-Sivak | L. Rudenko | V. Matyushenko | E. Stepanova | P. Prokopenko | I. Kudryavtsev | Alexandra Rak | Anna K. Chistyakova | A. Goshina
[1] D. van Baarle,et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets , 2022, bioRxiv.
[2] S. Ullah,et al. Next generation live-attenuated influenza vaccine platforms , 2022, Expert review of vaccines.
[3] G. Leroux-Roels,et al. Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine , 2022, Frontiers in Immunology.
[4] Diane J Post,et al. A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. , 2021, Vaccine.
[5] L. Rudenko,et al. Influenza vaccine: progress in a vaccine that elicits a broad immune response , 2021, Expert review of vaccines.
[6] L. Rudenko,et al. Universal Live-Attenuated Influenza Vaccine Candidates Expressing Multiple M2e Epitopes Protect Ferrets against a High-Dose Heterologous Virus Challenge , 2021, Viruses.
[7] Yu-Jin Jung,et al. Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin , 2021, Scientific Reports.
[8] J. Nguyen-Van-Tam,et al. Decline in Seasonal Influenza Vaccine Effectiveness With Vaccination Program Maturation: A Systematic Review and Meta-analysis , 2021, Open forum infectious diseases.
[9] Manish M Patel,et al. Effect of antigenic drift on influenza vaccine effectiveness in the United States - 2019-2020. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Yu-Jin Jung,et al. Generation and Characterization of Universal Live-Attenuated Influenza Vaccine Candidates Containing Multiple M2e Epitopes , 2020, Vaccines.
[11] Irina Isakova-Sivak,et al. Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses , 2020, Antiviral Research.
[12] K. Subbarao,et al. Live attenuated influenza vaccine. , 2020, Current topics in microbiology and immunology.
[13] L. Rudenko,et al. Insights into current clinical research on the immunogenicity of live attenuated influenza vaccines , 2020, Expert review of vaccines.
[14] R. Albrecht,et al. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge , 2019, Front. Immunol..
[15] J. Marvel,et al. OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes , 2019, npj Vaccines.
[16] L. Rudenko,et al. Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge , 2018, Vaccines.
[17] A. Egorov,et al. Enhancement of the immunogenicity of influenza a virus by the inhibition of immunosuppressive function of NS1 protein , 2018 .
[18] L. Rudenko,et al. Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine , 2018, Expert review of vaccines.
[19] R. Cox,et al. Improving influenza vaccines: challenges to effective implementation. , 2018, Current opinion in immunology.
[20] Louise A. Carolan,et al. Safety, immunogenicity and protection of A(H3N2) live attenuated influenza vaccines containing wild-type nucleoprotein in a ferret model. , 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[21] K. Kedzierska,et al. Live Attenuated Influenza Vaccines engineered to express the nucleoprotein of a recent isolate stimulate human influenza CD8+ T cells more relevant to current infections , 2018, Human vaccines & immunotherapeutics.
[22] Jan Kyncl,et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study , 2017, The Lancet.
[23] S. Takamura. Persistence in Temporary Lung Niches: A Survival Strategy of Lung-Resident Memory CD8+ T Cells , 2017, Viral immunology.
[24] L. Rudenko,et al. Immunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein , 2017, BioMed research international.
[25] L. Rudenko,et al. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories , 2016, Vaccine.
[26] Nicholas S. Kelley,et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. , 2016, The Lancet. Infectious diseases.
[27] R. Westermeier. Electrophoresis in Practice: A Guide to Methods and Applications of DNA and Protein Separations , 2016 .
[28] L. Rudenko,et al. Reassortant viruses for influenza vaccines: is it time to reconsider their genome structures? , 2016, Expert review of vaccines.
[29] R. Jacobi,et al. Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets , 2015, PloS one.
[30] Wenling Wang,et al. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice , 2015, Clinical and Vaccine Immunology.
[31] R. Siliciano,et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations , 2015, Nature.
[32] D. Marc. Influenza virus non-structural protein NS1: interferon antagonism and beyond. , 2014, The Journal of general virology.
[33] V. Egorov,et al. Molecular mechanisms enhancing the proteome of influenza A viruses: an overview of recently discovered proteins. , 2014, Virus research.
[34] B. Ferko,et al. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans. , 2014, Vaccine.
[35] M. Zheng,et al. Development of universal influenza vaccines based on influenza virus M and NP genes , 2014, Infection.
[36] Zhiqiang Liu,et al. Western Blot: Technique, Theory and Trouble Shooting , 2014, North American journal of medical sciences.
[37] T. Braciale,et al. Role of T cell immunity in recovery from influenza virus infection. , 2013, Current opinion in virology.
[38] D. Kelvin,et al. Extremely low vaccine effectiveness against influenza H3N2 in the elderly during the 2012/2013 flu season. , 2013, Journal of infection in developing countries.
[39] K. Kedzierska,et al. Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T‐cell responses , 2013, Immunology and cell biology.
[40] X. Wu,et al. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. , 2012, Vaccine.
[41] Ryan A. Langlois,et al. NS1-Truncated Live Attenuated Virus Vaccine Provides Robust Protection to Aged Mice from Viral Challenge , 2012, Journal of Virology.
[42] O. Pleguezuelos,et al. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. , 2012, Vaccine.
[43] M. Rose,et al. Mucosal immunity and nasal influenza vaccination , 2012, Expert review of vaccines.
[44] Tao Dong,et al. Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[45] N. Cox,et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). , 2011, Virology.
[46] A. Hill,et al. Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] R. Rappuoli,et al. Influenza vaccine immunology , 2011, Immunological reviews.
[48] E. Reinherz,et al. Significant Impact of Sequence Variations in the Nucleoprotein on CD8 T Cell-Mediated Cross-Protection against Influenza A Virus Infections , 2010, PloS one.
[49] T. Popow-Kraupp,et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. , 2010, The Journal of infectious diseases.
[50] Scott N. Mueller,et al. Immunization with Live Attenuated Influenza Viruses That Express Altered NS1 Proteins Results in Potent and Protective Memory CD8+ T-Cell Responses , 2009, Journal of Virology.
[51] J. Oxford,et al. Preclinical Evaluation of a Replication-Deficient Intranasal ΔNS1 H5N1 Influenza Vaccine , 2009, PloS one.
[52] F. Hayden,et al. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. , 2009, Vaccine.
[53] D. Voss,et al. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. , 2009, Vaccine.
[54] A. García-Sastre,et al. The NS1 Protein of a Human Influenza Virus Inhibits Type I Interferon Production and the Induction of Antiviral Responses in Primary Human Dendritic and Respiratory Epithelial Cells , 2009, Journal of Virology.
[55] T. Popow-Kraupp,et al. Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice. , 2009, The Journal of general virology.
[56] John Steel,et al. Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza , 2008, Journal of Virology.
[57] L. Stitz,et al. An antigenic epitope of influenza virus nucleoprotein (NP) associated with polymeric forms of NP , 2008, Virology Journal.
[58] M. Katze,et al. Functional Genomic and Serological Analysis of the Protective Immune Response Resulting from Vaccination of Macaques with an NS1-Truncated Influenza Virus , 2007, Journal of Virology.
[59] Adolfo García-Sastre,et al. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. , 2007, Vaccine.
[60] Larry R. Smith,et al. Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge , 2007, Human vaccines.
[61] A. Osterhaus,et al. Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by using virus-specific CD8+ T-cell clones. , 2007, The Journal of general virology.
[62] D. Bruder,et al. Cellular immunity and lung injury in respiratory virus infection. , 2006, Viral immunology.
[63] Thomas M. Moran,et al. Influenza Virus Evades Innate and Adaptive Immunity via the NS1 Protein , 2006, Journal of Virology.
[64] R. Webby,et al. Mutations in the NS1 Protein of Swine Influenza Virus Impair Anti-Interferon Activity and Confer Attenuation in Pigs , 2005, Journal of Virology.
[65] C. Walker,et al. Mutational escape from CD8+ T cell immunity , 2005, The Journal of experimental medicine.
[66] N. Bardiya,et al. Influenza vaccines: recent advances in production technologies , 2005, Applied Microbiology and Biotechnology.
[67] H. Katinger,et al. Immunogenicity and Protection Efficacy of Replication-Deficient Influenza A Viruses with Altered NS1 Genes , 2004, Journal of Virology.
[68] D. Levy,et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. , 1998, Virology.
[69] A. Monto,et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. , 1993, The Journal of infectious diseases.
[70] B. Moss,et al. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[71] Li-mei Chen,et al. Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model. , 2017, Virology.
[72] Caitlin E. Mullarkey,et al. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[73] Nicholas S. Kelley,et al. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.
[74] A. García-Sastre,et al. Attenuated influenza virus vaccines with modified NS1 proteins. , 2009, Current topics in microbiology and immunology.